Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CivaDerm refers to two distinct products marketed under the same name. 1. In the United States, **CivaDerm** is an FDA-approved, polymer-encapsulated, low dose rate (LDR) brachytherapy device designed for intra-operative or surface radiation treatment of skin cancer and other superficial lesions. It incorporates radioactive palladium (same as CivaSheet), features gold shielding for one-sided application, and is worn as a bandage for approximately five days to fully deliver the prescribed radiation dose. 2. In India and other markets, **CivaDerm** is a topical pharmaceutical (cream or shampoo) containing ciclopirox or a ciclopirox plus zinc pyrithione combination. It is used as an antifungal agent for external use in the treatment of dandruff, seborrheic dermatitis, fungal skin infections, and fungal nail infections. Its primary mechanism is the inhibition of fungal cell growth by interfering with cell membrane function[1][2][5][7][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CivaDerm.